4//SEC Filing
Campbell Bradley L 4
Accession 0001193125-25-323151
CIK 0001178879other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 6:21 PM ET
Size
8.7 KB
Accession
0001193125-25-323151
Insider Transaction Report
Form 4
Campbell Bradley L
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$9.03/sh+70,426$635,947→ 1,207,708 total - Sale
Common Stock
2025-12-15$10.86/sh−77,926$846,011→ 1,129,782 total - Exercise/Conversion
Stock Options (right to buy)
2025-12-15−70,426→ 0 totalExercise: $9.03Exp: 2026-01-04→ Common Stock (70,426 underlying)
Footnotes (2)
- [F1]This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.60 to $11.11 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]All of the options were fully vested and exercisable as of the transaction date.
Documents
Issuer
AMICUS THERAPEUTICS, INC.
CIK 0001178879
Entity typeother
Related Parties
1- filerCIK 0001400971
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 6:21 PM ET
- Size
- 8.7 KB